|
Gene: RPL37A |
Gene summary for RPL37A |
Gene summary. |
Gene information | Species | Human | Gene symbol | RPL37A | Gene ID | 6168 |
Gene name | ribosomal protein L37a | |
Gene Alias | L37A | |
Cytomap | 2q35 | |
Gene Type | protein-coding | GO ID | GO:0002181 | UniProtAcc | P61513 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6168 | RPL37A | A002-C-114 | Human | Colorectum | FAP | 2.01e-03 | -1.99e-01 | -0.1561 |
6168 | RPL37A | A015-C-104 | Human | Colorectum | FAP | 4.38e-13 | -3.18e-01 | -0.1899 |
6168 | RPL37A | A001-C-014 | Human | Colorectum | FAP | 9.47e-04 | -1.29e-01 | 0.0135 |
6168 | RPL37A | A002-C-016 | Human | Colorectum | FAP | 1.74e-05 | 2.87e-02 | 0.0521 |
6168 | RPL37A | A015-C-002 | Human | Colorectum | FAP | 9.02e-07 | -3.75e-01 | -0.0763 |
6168 | RPL37A | A001-C-203 | Human | Colorectum | FAP | 2.66e-04 | -1.68e-01 | -0.0481 |
6168 | RPL37A | A002-C-116 | Human | Colorectum | FAP | 2.67e-09 | -2.09e-01 | -0.0452 |
6168 | RPL37A | A014-C-008 | Human | Colorectum | FAP | 1.71e-03 | -2.86e-01 | -0.191 |
6168 | RPL37A | A018-E-020 | Human | Colorectum | FAP | 2.52e-04 | -2.27e-01 | -0.2034 |
6168 | RPL37A | F034 | Human | Colorectum | FAP | 1.32e-05 | -1.56e-01 | -0.0665 |
6168 | RPL37A | CRC-1-8810 | Human | Colorectum | CRC | 2.79e-33 | 9.19e-01 | 0.6257 |
6168 | RPL37A | AEH-subject1 | Human | Endometrium | AEH | 1.83e-58 | -5.22e-01 | -0.3059 |
6168 | RPL37A | AEH-subject2 | Human | Endometrium | AEH | 4.35e-46 | -6.22e-01 | -0.2525 |
6168 | RPL37A | AEH-subject3 | Human | Endometrium | AEH | 1.78e-58 | -5.53e-01 | -0.2576 |
6168 | RPL37A | AEH-subject4 | Human | Endometrium | AEH | 1.34e-54 | -7.32e-01 | -0.2657 |
6168 | RPL37A | AEH-subject5 | Human | Endometrium | AEH | 5.84e-58 | -7.18e-01 | -0.2953 |
6168 | RPL37A | EEC-subject1 | Human | Endometrium | EEC | 2.14e-58 | -6.16e-01 | -0.2682 |
6168 | RPL37A | EEC-subject2 | Human | Endometrium | EEC | 1.51e-13 | -3.01e-01 | -0.2607 |
6168 | RPL37A | EEC-subject4 | Human | Endometrium | EEC | 5.14e-107 | -9.46e-01 | -0.2571 |
6168 | RPL37A | EEC-subject5 | Human | Endometrium | EEC | 7.16e-63 | -7.34e-01 | -0.249 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000218110 | Cervix | CC | cytoplasmic translation | 96/2311 | 148/18723 | 4.87e-51 | 2.91e-47 | 96 |
GO:000218115 | Cervix | HSIL_HPV | cytoplasmic translation | 86/737 | 148/18723 | 3.97e-82 | 1.91e-78 | 86 |
GO:000218125 | Cervix | N_HPV | cytoplasmic translation | 42/534 | 148/18723 | 2.61e-30 | 1.19e-26 | 42 |
GO:0002181 | Colorectum | AD | cytoplasmic translation | 109/3918 | 148/18723 | 3.40e-43 | 2.13e-39 | 109 |
GO:00021811 | Colorectum | SER | cytoplasmic translation | 102/2897 | 148/18723 | 1.38e-48 | 8.49e-45 | 102 |
GO:00021812 | Colorectum | MSS | cytoplasmic translation | 108/3467 | 148/18723 | 1.78e-47 | 1.11e-43 | 108 |
GO:00021813 | Colorectum | MSI-H | cytoplasmic translation | 100/1319 | 148/18723 | 1.50e-79 | 8.31e-76 | 100 |
GO:00021814 | Colorectum | FAP | cytoplasmic translation | 76/2622 | 148/18723 | 3.31e-27 | 2.03e-23 | 76 |
GO:00021815 | Colorectum | CRC | cytoplasmic translation | 70/2078 | 148/18723 | 1.53e-28 | 9.16e-25 | 70 |
GO:000218116 | Endometrium | AEH | cytoplasmic translation | 104/2100 | 148/18723 | 1.01e-64 | 6.07e-61 | 104 |
GO:000218117 | Endometrium | EEC | cytoplasmic translation | 104/2168 | 148/18723 | 2.53e-63 | 1.52e-59 | 104 |
GO:000218127 | Esophagus | HGIN | cytoplasmic translation | 108/2587 | 148/18723 | 1.70e-60 | 1.02e-56 | 108 |
GO:0002181111 | Esophagus | ESCC | cytoplasmic translation | 135/8552 | 148/18723 | 4.17e-32 | 2.65e-29 | 135 |
GO:00021817 | Liver | NAFLD | cytoplasmic translation | 93/1882 | 148/18723 | 1.44e-55 | 8.41e-52 | 93 |
GO:000218112 | Liver | Cirrhotic | cytoplasmic translation | 120/4634 | 148/18723 | 2.95e-47 | 1.85e-43 | 120 |
GO:000218122 | Liver | HCC | cytoplasmic translation | 132/7958 | 148/18723 | 9.09e-33 | 5.76e-30 | 132 |
GO:000218132 | Liver | Cyst | cytoplasmic translation | 70/496 | 148/18723 | 9.01e-71 | 3.85e-67 | 70 |
GO:00021818 | Lung | IAC | cytoplasmic translation | 85/2061 | 148/18723 | 3.11e-43 | 1.85e-39 | 85 |
GO:000218113 | Lung | AIS | cytoplasmic translation | 85/1849 | 148/18723 | 5.48e-47 | 3.19e-43 | 85 |
GO:000218123 | Lung | AAH | cytoplasmic translation | 64/613 | 148/18723 | 1.74e-55 | 7.99e-52 | 64 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa0517145 | Cervix | N_HPV | Coronavirus disease - COVID-19 | 47/349 | 232/8465 | 1.79e-20 | 4.86e-18 | 3.80e-18 | 47 |
hsa0301045 | Cervix | N_HPV | Ribosome | 39/349 | 167/8465 | 2.05e-19 | 2.79e-17 | 2.18e-17 | 39 |
hsa0517155 | Cervix | N_HPV | Coronavirus disease - COVID-19 | 47/349 | 232/8465 | 1.79e-20 | 4.86e-18 | 3.80e-18 | 47 |
hsa0301055 | Cervix | N_HPV | Ribosome | 39/349 | 167/8465 | 2.05e-19 | 2.79e-17 | 2.18e-17 | 39 |
hsa03010 | Colorectum | AD | Ribosome | 96/2092 | 167/8465 | 8.28e-20 | 5.54e-18 | 3.54e-18 | 96 |
hsa05171 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
hsa030101 | Colorectum | AD | Ribosome | 96/2092 | 167/8465 | 8.28e-20 | 5.54e-18 | 3.54e-18 | 96 |
hsa051711 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
hsa030102 | Colorectum | SER | Ribosome | 92/1580 | 167/8465 | 2.21e-26 | 3.66e-24 | 2.66e-24 | 92 |
hsa051712 | Colorectum | SER | Coronavirus disease - COVID-19 | 98/1580 | 232/8465 | 3.33e-17 | 8.50e-16 | 6.17e-16 | 98 |
hsa030103 | Colorectum | SER | Ribosome | 92/1580 | 167/8465 | 2.21e-26 | 3.66e-24 | 2.66e-24 | 92 |
hsa051713 | Colorectum | SER | Coronavirus disease - COVID-19 | 98/1580 | 232/8465 | 3.33e-17 | 8.50e-16 | 6.17e-16 | 98 |
Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPL37A | insertion | In_Frame_Ins | novel | c.185_187dupAGA | p.Lys62dup | p.K62dup | P61513 | protein_coding | TCGA-EW-A2FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | goserelin | SD | ||
RPL37A | SNV | Missense_Mutation | c.110N>C | p.Tyr37Ser | p.Y37S | P61513 | protein_coding | deleterious(0.01) | benign(0.131) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
RPL37A | insertion | Frame_Shift_Ins | novel | c.213_214insGGTTTCGTTGGGTTGAATTTAGGGAAAACTAGGTCATATGT | p.Asn72GlyfsTer22 | p.N72Gfs*22 | P61513 | protein_coding | TCGA-BG-A0LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
RPL37A | SNV | Missense_Mutation | rs767492787 | c.181A>G | p.Met61Val | p.M61V | P61513 | protein_coding | tolerated(0.5) | benign(0.01) | TCGA-85-8481-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |